192 related articles for article (PubMed ID: 23246470)
1. Stability of whole inactivated influenza virus vaccine during coating onto metal microneedles.
Choi HJ; Bondy BJ; Yoo DG; Compans RW; Kang SM; Prausnitz MR
J Control Release; 2013 Mar; 166(2):159-71. PubMed ID: 23246470
[TBL] [Abstract][Full Text] [Related]
2. Cross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles.
Kim YC; Yoo DG; Compans RW; Kang SM; Prausnitz MR
J Control Release; 2013 Dec; 172(2):579-88. PubMed ID: 23643528
[TBL] [Abstract][Full Text] [Related]
3. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity.
Kim YC; Quan FS; Compans RW; Kang SM; Prausnitz MR
J Control Release; 2010 Mar; 142(2):187-95. PubMed ID: 19840825
[TBL] [Abstract][Full Text] [Related]
4. Stability kinetics of influenza vaccine coated onto microneedles during drying and storage.
Kim YC; Quan FS; Compans RW; Kang SM; Prausnitz MR
Pharm Res; 2011 Jan; 28(1):135-44. PubMed ID: 20387097
[TBL] [Abstract][Full Text] [Related]
5. Stability of influenza vaccine coated onto microneedles.
Choi HJ; Yoo DG; Bondy BJ; Quan FS; Compans RW; Kang SM; Prausnitz MR
Biomaterials; 2012 May; 33(14):3756-69. PubMed ID: 22361098
[TBL] [Abstract][Full Text] [Related]
6. Formulation of microneedles coated with influenza virus-like particle vaccine.
Kim YC; Quan FS; Compans RW; Kang SM; Prausnitz MR
AAPS PharmSciTech; 2010 Sep; 11(3):1193-201. PubMed ID: 20676947
[TBL] [Abstract][Full Text] [Related]
7. Effect of Osmotic Pressure on the Stability of Whole Inactivated Influenza Vaccine for Coating on Microneedles.
Choi HJ; Song JM; Bondy BJ; Compans RW; Kang SM; Prausnitz MR
PLoS One; 2015; 10(7):e0134431. PubMed ID: 26230936
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Stability of Inactivated Influenza Vaccine Encapsulated in Dissolving Microneedle Patches.
Chu LY; Ye L; Dong K; Compans RW; Yang C; Prausnitz MR
Pharm Res; 2016 Apr; 33(4):868-78. PubMed ID: 26620313
[TBL] [Abstract][Full Text] [Related]
9. Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin.
Quan FS; Kim YC; Yoo DG; Compans RW; Prausnitz MR; Kang SM
PLoS One; 2009 Sep; 4(9):e7152. PubMed ID: 19779615
[TBL] [Abstract][Full Text] [Related]
10. Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures.
Geeraedts F; Saluja V; ter Veer W; Amorij JP; Frijlink HW; Wilschut J; Hinrichs WL; Huckriede A
AAPS J; 2010 Jun; 12(2):215-22. PubMed ID: 20195930
[TBL] [Abstract][Full Text] [Related]
11. Development of the novel coating formulations for skin vaccination using stainless steel microneedle.
Kim SJ; Shin JH; Noh JY; Song CS; Kim YC
Drug Deliv Transl Res; 2016 Oct; 6(5):486-97. PubMed ID: 27519363
[TBL] [Abstract][Full Text] [Related]
12. Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens.
Kommareddy S; Baudner BC; Oh S; Kwon SY; Singh M; O'Hagan DT
J Pharm Sci; 2012 Mar; 101(3):1021-7. PubMed ID: 22190403
[TBL] [Abstract][Full Text] [Related]
13. Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization.
Quan FS; Kim YC; Vunnava A; Yoo DG; Song JM; Prausnitz MR; Compans RW; Kang SM
J Virol; 2010 Aug; 84(15):7760-9. PubMed ID: 20484519
[TBL] [Abstract][Full Text] [Related]
14. Formulation Approach that Enables the Coating of a Stable Influenza Vaccine on a Transdermal Microneedle Patch.
Ameri M; Ao Y; Lewis H
AAPS PharmSciTech; 2021 Jun; 22(5):175. PubMed ID: 34114100
[TBL] [Abstract][Full Text] [Related]
15. Effect of zymosan and poly (I:C) adjuvants on responses to microneedle immunization coated with whole inactivated influenza vaccine.
Shin JH; Noh JY; Kim KH; Park JK; Lee JH; Jeong SD; Jung DY; Song CS; Kim YC
J Control Release; 2017 Nov; 265():83-92. PubMed ID: 28890214
[TBL] [Abstract][Full Text] [Related]
16. Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch.
Kim YC; Song JM; Lipatov AS; Choi SO; Lee JW; Donis RO; Compans RW; Kang SM; Prausnitz MR
Eur J Pharm Biopharm; 2012 Jun; 81(2):239-47. PubMed ID: 22504442
[TBL] [Abstract][Full Text] [Related]
17. Physical and immunogenic stability of spray freeze-dried influenza vaccine powder for pulmonary delivery: comparison of inulin, dextran, or a mixture of dextran and trehalose as protectants.
Murugappan S; Patil HP; Kanojia G; ter Veer W; Meijerhof T; Frijlink HW; Huckriede A; Hinrichs WL
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):716-25. PubMed ID: 23933147
[TBL] [Abstract][Full Text] [Related]
18. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response.
Johansson BE; Matthews JT; Kilbourne ED
Vaccine; 1998; 16(9-10):1009-15. PubMed ID: 9682352
[TBL] [Abstract][Full Text] [Related]
19. An Improved Inactivated Influenza Vaccine with Enhanced Cross Protection.
Ni Y; Guo J; Turner D; Tizard I
Front Immunol; 2018; 9():1815. PubMed ID: 30140267
[TBL] [Abstract][Full Text] [Related]
20. Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy.
Fox CB; Barnes V L; Evers T; Chesko JD; Vedvick TS; Coler RN; Reed SG; Baldwin SL
Influenza Other Respir Viruses; 2013 Sep; 7(5):815-26. PubMed ID: 23122325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
